Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory

摘要: Abstract The treatment of heart failure with reduced ejection fraction (HFrEF) has changed considerably over time, particularly the sequential development therapies aimed at antagonism maladaptive biologic pathways, including inhibition of sympathetic nervous system and renin-angiotensin aldosterone system. nature earlier HFrEF trials allowed integration new tested against background therapy time. More recently, multiple are being evaluated simultaneously, number therapeutic choices for treating grown considerably. In addition, implementation science lagged behind discovery in failure. Furthermore, given there currently >200 ongoing clinical failure, further complexities anticipated. an effort to provide a decision-making framework current era expanding options HFrEF, Heart Failure Collaboratory convened multi-stakeholder group, patients, clinicians, investigators, U.S. Food Drug Administration, industry, payers who met Administration campus on March 6, 2020. This paper summarizes discussions expert consensus recommendations.